Illumina (NASDAQ:ILMN) Shares Sold by Rep. Gilbert Ray Cisneros, Jr.

by · The Cerbat Gem

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Illumina, Inc. (NASDAQ:ILMN). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Illumina stock on October 27th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

  • Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
  • Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
  • Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
  • Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
  • Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
  • Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
  • Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
  • Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
  • Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
  • Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.

Illumina Price Performance

Shares of ILMN traded down $3.38 on Thursday, reaching $209.55. The stock had a trading volume of 1,726,386 shares, compared to its average volume of 2,354,597. Illumina, Inc. has a twelve month low of $112.65 and a twelve month high of $309.35. The firm has a market capitalization of $31.68 billion, a PE ratio of 40.56, a PEG ratio of 2.89 and a beta of 1.46. The firm has a 50-day moving average of $249.32 and a 200 day moving average of $179.36. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. During the same period in the previous year, the firm posted $1.34 earnings per share. Illumina’s revenue was up 4.2% on a year-over-year basis. Sell-side analysts expect that Illumina, Inc. will post 5.43 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on ILMN. UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and raised their target price for the company from $135.00 to $260.00 in a report on Wednesday, September 9th. Guggenheim increased their price target on shares of Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. Stephens downgraded Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price objective for the company. in a research report on Friday, October 23rd. Finally, Evercore reaffirmed an “underperform” rating on shares of Illumina in a research note on Friday, October 30th. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $244.24.

Check Out Our Latest Stock Report on ILMN

Insider Buying and Selling

In other news, CAO Scott D. Ericksen sold 267 shares of the company’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $217.76, for a total transaction of $58,141.92. Following the completion of the sale, the chief accounting officer directly owned 14,029 shares in the company, valued at $3,054,955.04. This represents a 1.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 98,833 shares of the stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $216.87, for a total value of $21,433,912.71. Following the completion of the transaction, the director directly owned 208,826 shares in the company, valued at $45,288,094.62. This trade represents a 32.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 1,881,899 shares of company stock valued at $415,905,954. 2.90% of the stock is owned by insiders.

More Illumina News

Investors following ILMN have been watching these news items:

  • Positive Sentiment: Illumina reported third-quarter revenue of $1.129 billion and net income of $220 million, raised its 2026 revenue outlook to $4.64 billion–$4.66 billion, and highlighted strength in clinical sequencing consumables. How Investors May Respond To Illumina (ILMN) Earnings Beat
  • Positive Sentiment: The company expanded its molecular residual disease research portfolio with an ultrasensitive duplex sequencing workflow for circulating tumor DNA and was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments support its push into clinical oncology and sequencing applications. Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
  • Negative Sentiment: Director Keith Meister sold 280,091 shares over November 9–11 for approximately $61.1 million, reducing his direct holdings to 208,826 shares. The scale of the sales could raise concerns among investors, despite his continuing substantial ownership. SEC filing

Hedge Funds Weigh In On Illumina

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Illumina in the 2nd quarter valued at about $3,374,423,000. Plato Investment Management Ltd purchased a new position in shares of Illumina during the 2nd quarter worth about $948,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Illumina during the 2nd quarter worth about $30,501,000. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Illumina in the second quarter worth approximately $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in shares of Illumina in the second quarter worth approximately $6,711,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Illumina Company Profile

(Get Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Featured Articles